EULAR pediatric sessions to highlight big data, personalized medicine

Other talks in the session will cover signaling pathways in childhood systemic lupus erythematosus (SLE), galectin-9 as a biomarker in juvenile dermatomyositis, and evidence from the phase 3 PRINTO trial on how best to taper corticosteroids in patients with new-onset juvenile dermatomyositis.

Another crucial topic in pediatric rheumatology is systemic hyperinflammation, a potentially life-threatening situation requiring rapid detection and treatment.

A Saturday morning session will dive deeply into this topic. First, Sebastiaan Vastert, MD, PhD, will share a birds-eye view of systemic inflammation in JIA, setting the stage for a discussion by Angelo Ravelli, MD, of challenges in diagnosing macrophage activation syndrome, which disproportionately affects JIA patients.

Also during the session, Fabrizio de Benedetti, MD, PhD, will review new findings on the pathogenesis of hyperinflammation and how they can guide therapeutic development. Rounding off the session, Rebecca Davies will present research on first-onset uveitis in patients receiving etanercept or methotrexate to treat JIA. “Attendees will learn new insights about diagnosing and treating systemic inflammation in children,” Dr. Prakken said.